ICON ANNOUNCES MAJOR SURGE IN PAT BY OVER 158% FOR Q3 2024
Icon Offshore Berhad (“ICON”), a leading offshore support vessel provider, delivered a strong performance in Q3 2024, reporting a 167.8% increase in profit before tax (PBT) to RM23.4 million and a 158.2% rise in profit after tax (PAT) to RM18.3 million. Revenue climbed 20.7% year-on-year to RM70.6 million, driven by higher daily charter rates under long-term contracts.
FARM FRESH ACHIEVES 185.9% LEAP IN PROFIT AFTER TAX
Farm Fresh Berhad reported a 25.6% year-on-year revenue growth to RM249.2 million, its highest ever, and a 106% increase in PAT to RM27.0 million for Q2 FY2025.
Strong demand in the HORECA sector, new product launches, and improved margins drove growth, alongside a turnaround in its Australia operations. The Group also advanced sustainability efforts and expanded its Milk on Tap program.
OPTIMAX YET AGAIN DELIVERS RECORD QUARTERLY REVENUE
Optimax Holdings Berhad (“Optimax”) reported a 16.0% increase in Q3FY2024 revenue to RM33.1 million, driven by new satellite clinics. Despite higher operating costs, profit before tax (PBT) and profit after tax (PAT) rose by 0.2% and 7.0%, respectively. For the 9 months, revenue grew by 13.1%, with PBT and PAT also increasing. CEO Sandy Tan highlighted the success of their clinic expansion strategy and remains optimistic about future growth. An interim dividend of 0.8 sen per share has been declared, payable on 30 December 2024.
SENI JAYA REPORTS STRONG TURNAROUND IN Q1FYE2025
Seni Jaya Corporation Berhad reported a strong Q1FYE2025 performance, with revenue surging 64.5% year-on-year to RM17.6 million and PATAMI rising 237.5% to RM2.7 million. The turnaround was fueled by robust demand for digital billboards, contributing RM4.8 million in revenue.
T7 GLOBAL POSTS 42.1% GROWTH IN PATAMI FOR 9MFYE2024
T7 Global Berhad (“T7 Global”) delivered a strong Q3FYE2024, reporting revenue of RM176.4 million and PATAMI of RM11.4 million, marking Y-o-Y growth of 28.4% and 42.1% respectively. For the cumulative 9 months, revenue reached RM458.9 million (+36.8%), with PATAMI at RM26.6 million (+42.1%), driven by a 108.4% surge in the Industrial Solutions division.
KERJAYA PROSPEK REPORTS RM1.24 BILLION IN REVENUE FOR 9MFYE2024
Kerjaya Prospek Group Berhad (“Kerjaya”) posted strong Q3FYE2024 results with PATAMI up 29.5% year-on-year to RM46.1 million and revenue rising 39.4% to RM504.8 million, driven by progress in construction projects.
For 9MFYE2024, PATAMI grew 20.9% to RM116.7 million, with revenue reaching RM1.24 billion. Kerjaya’s order book stands at RM4.4 billion, supported by a strong net cash position of RM260.2 million.
CEO Tee Eng Tiong highlighted strategic growth, including a 36-acre Penang development, and announced total dividends of 12.0 sen per share for FY2024, yielding approximately 5.6%.
UEM Edgenta Sustains Steady Growth in Q3 2024, Showcasing Robust Resilience and Strategic Progress
UEM Edgenta Berhad reported strong Q3 FY2024 results, with year-to-date revenue up 7.6% to RM2.23 billion and net profit rising 16.8% to RM33.4 million. Q3 net profit nearly doubled to RM10.4 million.
Key highlights include a RM9.1 billion order book, RM277 million in new contracts, and RM900 million secured in Singapore healthcare services. Cost-saving initiatives under Edgenta of The Future 2025 achieved RM100 million ahead of schedule.
E&O POSTS REMARKABLE 60.9% REVENUE GROWTH FOR 1HFYE2025
Eastern & Oriental Berhad (“E&O”) reported strong Q2FYE2025 results, with revenue rising 38% to RM171.0 million, driven by The Lume and ongoing developments. PAT increased 7% to RM33.6 million, while six-month revenue surged 60.9% to RM336.7 million, led by its properties segment.
Managing Director Kok Tuck Cheong highlighted robust demand for The Lume and announced plans to launch a waterfront serviced apartment on Andaman Island, aligning with the island’s RM60 billion masterplan. A special dividend of 1.0 sen per share has been proposed.
PHARMANIAGA MAINTAINS MOMENTUM IN STRONG RECOVERY
Pharmaniaga Berhad posted a remarkable recovery in Q3 FY2024, with PAT reaching RM101.3 million versus a RM49.0 million loss in Q3 FY2023. Nine-month revenue rose 8.4% to RM2.8 billion, driven by higher concession sales and market expansion.
Key milestones include launching Malaysia’s first insulin and vaccine manufacturing facility and securing NPRA approval for its insulin product. These achievements, alongside strategic funding and cost optimisation, reinforce Pharmaniaga’s growth trajectory and commitment to advancing healthcare
TALIWORKS ANNOUNCES Q3FYE2024 RESULTS
Taliworks Corporation Berhad (“Taliworks”) posted Q3FYE2024 revenue of RM158.0 million, supported by growth across all segments and government compensation. Profit after tax reached RM47.6 million.
For 9MFYE2024, revenue rose to RM350.3 million, driven by infrastructure projects, with PAT at RM84.5 million. A third interim dividend of 2.0 sen per share offers a 5.3% yield.
Executive Director Kevin Chin reaffirmed Taliworks’ commitment to Malaysia’s infrastructure development and the Water Sector Transformation 2040 agenda
